Repligen to Acquire BioLife Solutions in $11.25 Cash and Stock Deal to Expand Cell Processing Platform

Transaction Structure and Consideration Details

Repligen Corporation has structured the acquisition of BioLife Solutions through a combination merger arrangement involving two subsidiaries: Bravo Merger Sub I, Inc., a Delaware corporation wholly owned by Repligen, and Bravo Merger Sub II, LLC, a Delaware limited liability company also wholly owned by Repligen. The total consideration offered to BioLife shareholders comprises both cash and equity components, designed to provide stockholders with immediate liquidity and ongoing participation in the combined entity's future growth.

The per-share consideration package values BioLife's equity at $11.25 in cash combined with 0.1442 shares of Repligen common stock for each outstanding BioLife share. This mixed consideration structure reflects Repligen's confidence in the strategic value of the combination while also offering shareholders direct ownership participation in the enlarged enterprise. The agreement was formalized through execution of the Agreement and Plan of Merger dated July 21, 2026, between the three merger entities and BioLife Solutions, Inc., a Delaware corporation.

Strategic Rationale in the Cell Therapy Market

The transaction is positioned as a strategic expansion of Repligen's capabilities within the high-growth cell therapy industry. According to the announcement, BioLife Solutions operates as a highly differentiated cell processing tool leader, offering specialized technology platforms that support cell and gene therapy manufacturing processes. This acquisition allows Repligen to enhance its bioprocessing portfolio and strengthen its competitive position within an industry experiencing substantial growth momentum.

Repligen's leadership expressed confidence in the strategic fit of the combination. The company stated its belief that the transaction represents a financially compelling opportunity and is expected to be accretive in the near term. Additionally, the disclosure indicates that management anticipates the combined entity will benefit from accelerated profitable growth driven by expanded market opportunities and complementary technology platforms that address the evolving needs of cell therapy manufacturers and developers.

Operational Integration and Synergy Expectations

The announcement reflects management's expectation that the integration of BioLife's cell processing capabilities with Repligen's existing bioprocessing solutions will generate synergies and enhance revenue opportunities across the combined company's customer base. The transaction is intended to leverage BioLife's differentiated position within the cell therapy processing sector while expanding Repligen's reach into adjacent market segments that require specialized manufacturing tools and technologies.

Repligen and BioLife management teams have indicated that the transaction is expected to drive future growth through multiple mechanisms, including optimization of operational processes, cross-selling opportunities between the two companies' product portfolios, and the ability to serve customers more comprehensively across the cell therapy value chain. However, the realization of these anticipated synergies remains subject to successful integration execution and satisfaction of closing conditions outlined in the merger agreement.

Regulatory Approvals and Stockholder Voting Requirements

Completion of the transaction is contingent upon several closing conditions, including receipt of necessary regulatory approvals and approval from BioLife stockholders. The companies have disclosed that they anticipate filing a registration statement on Form S-4 with the Securities and Exchange Commission, which will contain a proxy statement for BioLife shareholders and a prospectus for Repligen. This registration statement will provide detailed information regarding the transaction, including financial impact assessments, risk factors, and governance matters relevant to stockholder consideration.

Both companies cautioned that there is inherent uncertainty regarding the timing and outcome of regulatory reviews, as well as the possibility that regulatory approvals could be conditioned upon requirements that might affect the anticipated benefits of the transaction. Additionally, the parties identified the risk that BioLife stockholder approval may not be obtained or that other closing conditions may not be satisfied on a timely basis. Investors are advised to consult the proxy statement/prospectus when filed for comprehensive information about voting procedures and the full range of transaction-related risks.

Financial and Market Position Considerations

The disclosure indicates that management believes the cell therapy market presents substantial growth opportunities and that BioLife maintains a strong market position within the cell processing technology segment. However, the companies acknowledged that there is inherent uncertainty regarding market size estimates and the accuracy of projections concerning BioLife's market trajectory. Should the addressable market prove smaller than anticipated or competitive conditions differ from current expectations, the realized benefits of the combination could differ materially from projections.

Repligen noted in its most recent quarterly report for the three months ended March 31, 2026, expectations for strong margin expansion and continued revenue growth. The acquisition is intended to complement this growth trajectory by adding BioLife's cell processing capabilities and customer relationships. Additional financial details regarding the anticipated impact of the transaction on Repligen's operating results and financial position will be disclosed in the Form S-4 registration statement and proxy materials when filed with the SEC.

Risk Factors and Integration Uncertainties

The companies identified multiple risk factors that could impede successful completion or realization of expected benefits from the transaction. These include the possibility of adverse regulatory developments, failure to obtain necessary governmental approvals, unexpected integration complexities, and the potential for diversion of management attention from ongoing business operations during the merger process. Additionally, the disclosure noted risks related to potential adverse reactions from employees and business partners, as well as uncertainty regarding the competitive landscape within the cell therapy manufacturing sector.

Repligen and BioLife cautioned that actual results could differ materially from management's forward-looking statements regarding transaction benefits, financial impact, revenue growth, and market opportunities. The companies identified several factors that have historically affected their results and could do so in the future, including economic conditions, competitive pressures, regulatory developments, and execution risks inherent in large-scale business combinations. Investors are encouraged to review detailed risk disclosures in the companies' recent annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC.

Timing and Closing Conditions

The merger agreement contains customary closing conditions that must be satisfied or waived before the transaction can be completed. While the companies have not disclosed a specific anticipated closing date in this announcement, they have indicated expectations regarding the timing of regulatory processes and stockholder approval procedures. Completion of the transaction remains subject to satisfaction of all conditions outlined in the merger agreement, which could include antitrust clearance, state regulatory approvals, and other standard closing conditions typical for transactions of this nature and size.

The disclosure notes that either party may have the right to terminate the merger agreement under specified circumstances, including the occurrence of events that could adversely affect the transaction's anticipated benefits or the parties' ability to satisfy closing conditions. Investors should monitor the regulatory filing process and the SEC's website for updates regarding the progress of approvals and anticipated closing timelines as additional information becomes available.

Management Commentary and Strategic Vision

Repligen's Chief Executive Officer, Olivier Loeillot, posted commentary on LinkedIn on July 22, 2026, in connection with the announcement of the merger agreement. The filing reflects management's conviction that the combination represents a strategically sound and financially compelling opportunity for Repligen shareholders. The CEO's public comments indicated enthusiasm for accelerating the company's growth within the cell therapy sector through the acquisition of BioLife's specialized processing platform capabilities.

The strategic messaging emphasizes BioLife's differentiation within the cell processing landscape and the complementary nature of the two companies' technology platforms. Management's vision, as reflected in the announcement materials, centers on leveraging the combined entity's expanded capabilities to capture growth opportunities in the rapidly expanding cell and gene therapy manufacturing space. However, these forward-looking statements are subject to the risks and uncertainties disclosed throughout the announcement materials.

Investor Information and Document Availability

Repligen and BioLife have advised investors and security holders to review the proxy statement/prospectus and other relevant materials when filed with the SEC, as these documents will contain comprehensive information about the transaction, including detailed financial analyses, risk assessments, and governance information. Both companies have established dedicated processes for making transaction-related documents available to investors free of charge through their corporate websites and by request, as well as through the SEC's Electronic Data Gathering, Analysis, and Retrieval system.

The companies have emphasized that all forward-looking statements contained in transaction announcements speak only as of the date made and are based on management's current expectations and beliefs. Neither Repligen nor BioLife has undertaken any obligation to update or revise forward-looking statements to reflect subsequent changes in expectations, business developments, or market conditions. Investors are advised to obtain and carefully review all filed documents before making investment decisions related to either company.